Epigenetic aging and blood based neurodegeneration markers in LASI-DAD [0.03%]
表观遗传衰老和基于血液的神经退行性标志物的LASI研究
Jung Ki Kim,Thalida E Arpawong,Bharat Thyagarajan et al.
Jung Ki Kim et al.
DNA methylation (DNAm)-based epigenetic clocks are emerging biomarkers of biological aging and have been linked to cognitive decline and dementia, but their relationship with blood-based neurodegenerative biomarkers remains understudied in ...
Interaction of diet and physical activity on dementia risk: the Rotterdam study [0.03%]
饮食和身体活动对痴呆风险的交互作用：旋转椅研究
Muhammed Lamin Sambou,M Arfan Ikram,M Kamran Ikram et al.
Muhammed Lamin Sambou et al.
Background: Diet and physical activity have been reported as independent risk factors for dementia, but few published studies have investigated the interactive effects of the two on dementia risk. Understanding their syne...
Phenotyping of mild behavioral impairment domains in multi-regional dementia-free older adults of Chinese ethnicity: impulse dyscontrol as the leading domain [0.03%]
汉族多地区轻度行为异常表型分域在无痴呆老年人中的特征分布：行为冲动失控为主导领域
Yingqi Liao,Yaping Zhang,Haoran Zhang et al.
Yingqi Liao et al.
Background: Mild behavioral impairment (MBI) is an early neurobehavioral marker of dementia, yet MBI domain patterns remain underexplored among populations of Chinese ethnicity. This study aimed to characterize MBI domain...
Top five Alzheimer Disease trial eligibility criteria favor men compared to women in a clinic-based cohort [0.03%]
基于门诊队列的阿尔茨海默病临床试验纳入标准对男性有利
Lieza G Exalto,Siti S Syaziyah,Xiaotian T Fang et al.
Lieza G Exalto et al.
Background: Less women participate in Alzheimer Disease (AD) trials compared to their estimated representation in the global dementia population. Objectiv...
RNA-based therapeutics for Alzheimer's disease and related tauopathies: challenges and opportunities [0.03%]
阿尔茨海默病及相关Tau蛋白疾病的RNA药物治疗：挑战与机遇
Binita Rajbanshi,Ilaria Brentari,Michela Alessandra Denti et al.
Binita Rajbanshi et al.
Tauopathies are neurodegenerative diseases characterized by pathological tau protein accumulation. Though therapies involving monoclonal antibodies and small-molecule inhibitors have progressed, they have so far failed in multiple clinical ...
Beyond amyloid positivity: Biological heterogeneity in the real-world use of lecanemab [0.03%]
超越淀粉样蛋白阳性：在真实世界中使用乐卡尼马布的生物异质性
Michael S Rafii
Michael S Rafii
Sleep complaints and genetic risk of Alzheimer's disease in older women: associations with memory and tau deposition [0.03%]
睡眠问题和阿尔茨海默病遗传风险在老年女性中的关联：对记忆和tau蛋白沉积的影响
Kitty K Lui,Xin Wang,Melanie A Dratva et al.
Kitty K Lui et al.
Background: Emerging evidence point to a bidirectional relationship between sleep disturbances and Alzheimer's disease (AD). Poor sleep may be an overlooked risk factor for older women, who are disproportionately affected...
Clarity AD open-label extension data do not robustly confirm disease course modification by lecanemab in ApoE4 heterozygotes and non-carriers [0.03%]
clarity AD开放标签延伸研究数据并未有力证明lecanemab可改变ApoE4杂合子和非携带者的疾病进程
Jemma Hazan,Kathy Y Liu,Robert Howard
Jemma Hazan
Adapting the spanish healthcare system for disease-modifying treatments in early-stage alzheimer's disease [0.03%]
西班牙卫生系统适应阿尔茨海默病早期阶段的疾病修正治疗
R Sánchez Valle,A Lleó Bisa,A Villarejo Galende et al.
R Sánchez Valle et al.
Background: The emergence of disease-modifying therapies targeting amyloid pathology represents a major paradigm shift in the management of Alzheimer disease (AD). However, their implementation poses substantial organizat...
Hazan J; Liu KY; Howard R. Clarity AD open-label extension data do not robustly confirm disease course modification by lecanemab in ApoE4 heterozygotes and non-carriers. # TJPAD-D-26-00165 [0.03%]
Hazan J; Liu KY; Howard R. Clarity AD开放标签扩展数据未能有力证实Lecanemab可改变ApoE4杂合子和非携带者的疾病进程。# TJPAD-D-26-00165
Lutz Froelich
Lutz Froelich